(NASDAQ: IOVA) Iovance Biotherapeutics's forecast annual revenue growth rate of 616.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Iovance Biotherapeutics's revenue in 2024 is $1,189,000.On average, 7 Wall Street analysts forecast IOVA's revenue for 2024 to be $44,813,418,514, with the lowest IOVA revenue forecast at $9,272,993,828, and the highest IOVA revenue forecast at $76,563,646,627. On average, 5 Wall Street analysts forecast IOVA's revenue for 2025 to be $91,696,502,217, with the lowest IOVA revenue forecast at $36,449,569,112, and the highest IOVA revenue forecast at $143,563,820,102.
In 2026, IOVA is forecast to generate $117,715,908,422 in revenue, with the lowest revenue forecast at $33,796,152,203 and the highest revenue forecast at $233,481,136,455.